1 / 21

Advances in Melanoma: Vaccines Doug Schwartzentruber, M.D., FACS System Medical Director for Cancer Indiana University H

Advances in Melanoma: Vaccines Doug Schwartzentruber, M.D., FACS System Medical Director for Cancer Indiana University Health Associate Director, IU Simon Cancer Center Indianapolis, IN. Disclosures. Medical Advisory Board: Prometheus Speaker: Zyopharm Oncology, Inc.

terris
Download Presentation

Advances in Melanoma: Vaccines Doug Schwartzentruber, M.D., FACS System Medical Director for Cancer Indiana University H

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Advances in Melanoma: Vaccines Doug Schwartzentruber, M.D., FACS System Medical Director for Cancer Indiana University Health Associate Director, IU Simon Cancer Center Indianapolis, IN

  2. Disclosures Medical Advisory Board: Prometheus Speaker: Zyopharm Oncology, Inc

  3. Incidence and Mortality of Cancer Jemal A. , et. al., CA Cancer J Clin 60:277-300,2010

  4. Rising Incidence of Melanoma

  5. Metastatic Melanoma Treated With IL-2 Courtesy of S. Rosenberg

  6. A Phase III Multi-institutional Randomized Study of Immunization with gp100:209-217(210M) Peptide Followed by High Dose IL-2 vs High Dose IL-2 Alone in Patients With Metastatic Melanoma

  7. BackgroundTreatment with IL-2 and gp100:209-217(210M) • Atkins M.B., et. al., J ClinOnc 17: 2105-2116, 1999. • Rosenberg S.A., et. al., Nature Medicine 4: 321-327, 1998. • Smith F.O., et. Al., Clin Cancer Res 14:5610-5618, 2008. IL-2 alone response rate (RR): 16%.1 gp100 209-217 (210M) + IL-2 every 3 weeks, RR 42% (13/31).2 Retrospective results NCI: IL-2 alone (n=305) RR 12.8 %; gp100 + IL-2 (n=49) RR 25.0 %.3

  8. Rationale:Gp 100 Vaccine + IL-2 Induces Tumor Destruction Tumors Vaccine Induces Anti-Tumor T-cells Vaccine T-cells IL-2 T-Cells Destroy Tumors IL-2 Induces T-Cell Proliferation

  9. Treatment Schema: 2-Arm Randomized Studyfor Patients with Metastatic Melanoma IL-2 Primary Endpoint:Clinical Response IL-2 Plus Vaccine

  10. Treatment: IL-2 Doses (mean) Patients 93 85 75 72 29 39 26 37

  11. More Clinical Responses were Seen inPatients Receiving IL-2 + Gp100 Vaccine 20.0% 9.7%

  12. Progression Free Survival is Enhancedwith Gp100 Vaccine Median Survival months (95% CI) IL-2 Alone: 1.6 (1.5-1.8) IL-2+gp100: 2.2 (1.7-3.9) p value: 0.008 Schwartzentruber D. J. et al., NEJM, 2011

  13. Trend for Increased Overall Survivalwith Gp100 Vaccine Median Survival months (95% CI) IL-2 Alone: 11.1 (8.7-16.3) IL-2+gp100: 17.8 (11.9-25.8) p value: 0.06 Schwartzentruber D. J. et al., NEJM, 2011

  14. Conclusions • gp100 209-217 (210M) in Montanide ISA 51 enhances the clinical activity of HD IL-2 in patients with metastatic melanoma. • Rational combinations of vaccines and immunomodulatory agents with IL-2 need to be further studied in the treatment of patients with metastatic melanoma.

  15. Future Peptide Vaccine Studies • Develop a more potent vaccine. • Perform a larger randomized trial to test the new vaccine.

  16. Thank you In-vitro Studies Lien Ngo, MS Steven Rosenberg, MD Nurses & Data Managers

  17. Immunotherapy of advanced melanoma by intra-tumoral injections of autologous, purified dendritic cells transducedwith gene construct of interleukin-12, with dose-dependent expression under the control of an oral activator ligand D.J. Schwartzentruber¹, J.M. Kirkwood², M. Guarino³, J. Richards⁴, O. Hamid⁵, S. O’Day⁵, J. Nemunaitis⁶; J. Talmadge⁷, S. Chada⁸, K. Menander⁹, K. Shafer-Weaver⁸, J. Senesac⁸, M. O. Thornton¹⁰, J. J. Lewis¹⁰, and R.B. Herberman⁸ ¹Indiana University Health Goshen Center for Cancer Care, Goshen, IN; ²University of Pittsburgh Cancer Institute, Pittsburgh, PA; ³Christiana Care Health Services, Inc, Newark, DE; ⁴Oncology Specialists, S.C., Park Ridge, IL; ⁵The Angeles Clinic & Research Institute, Los Angeles, CA; ⁶Mary Crowley Cancer Research Center, Dallas, TX; ⁷Univ. of Nebraska Med Ctr., Omaha, NE; ⁸Intrexon Corporation, Germantown, MD; ⁹Menander and Associates, Bellaire, TX; ¹⁰ZIOPHARM Oncology, Inc., Boston, MA

  18. RheoSwitch® + Activator Ligand Controls Timing and Level of Target Gene Expression RheoSwitch Protein 1 RheoSwitch Protein 2 Co-repressor protein RheoSwitch components Inducible Promoter Target Gene Ligand Basal Transcription Proteins RheoSwitch components Co-activator protein

  19. Ad-DC-RTS-IL-12 + Ligand Approach Enables Centralized Manufacturing Efficiencies Centralized MFR Clinical Location Oral dosing per protocol Ad-RTS-IL-12 Activator Ligand INXN-2001 INXN-1001 Transduction Stimulating elutriation Factors Monocytes Leukapheresis iDC’s DC-RTS-IL-12 INXN-3001 Thaw DC’s and inject target tumor Cryoprotectant Freeze and Ship

  20. Patient 001 CT Scan of Supraclavicular Mass Pretreatment: 4/17/09 1 month after 4th treatment 2/4/10

  21. Conclusions • The Rheoswitch control of gene expression has been utilized for the first time in patients • Therapy with DC-RTS-IL-12+AL has overall been well tolerated • One partial response was observed in 8 evaluable patients with metastatic melanoma who had prior progressive disease despite other treatments • This therapeutic approach has the potential advantage, relative to single epitope melanoma vaccine of triggering anti-tumor immunity via different antigens in each patient, without the need to restrict eligibility to patients with a particular HLA type

More Related